Even though, to date, no FDA-approved drugs against this protein are on the market, many efforts have been made in the discovery of molecules capable of targeting AKT by binding to one of its three pockets [4,13,21], with particular emphasis on small molecules for cancer treatment [3,4,14]. This evidence concerns the gene AKT1 and cancer.